TY  - BOOK
AU  - Forrestal, Brian J
AU  - Iantorno, Micaela
AU  - Lipinski, Michael J
AU  - Torguson, Rebecca
AU  - Waksman, Ron
TI  - A comparison of the ultrathin Orsiro Hybrid sirolimus-eluting stent with contemporary drug-eluting stents: A meta-analysis of randomized controlled trials
SN  - 1878-0938
PY  - 2018///
KW  - *Cardiovascular Agents/ad [Administration & Dosage]
KW  - *Coronary Artery Disease/su [Surgery]
KW  - *Coronary Vessels/su [Surgery]
KW  - *Drug-Eluting Stents
KW  - *Percutaneous Coronary Intervention/is [Instrumentation]
KW  - *Sirolimus/ad [Administration & Dosage]
KW  - Aged
KW  - Cardiovascular Agents/ae [Adverse Effects]
KW  - Coronary Artery Disease/dg [Diagnostic Imaging]
KW  - Coronary Artery Disease/mo [Mortality]
KW  - Coronary Artery Disease/pp [Physiopathology]
KW  - Coronary Thrombosis/et [Etiology]
KW  - Coronary Vessels/dg [Diagnostic Imaging]
KW  - Coronary Vessels/pp [Physiopathology]
KW  - Female
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Myocardial Infarction/et [Etiology]
KW  - Percutaneous Coronary Intervention/ae [Adverse Effects]
KW  - Percutaneous Coronary Intervention/mo [Mortality]
KW  - Prosthesis Design
KW  - Randomized Controlled Trials as Topic
KW  - Risk Factors
KW  - Sirolimus/ae [Adverse Effects]
KW  - Time Factors
KW  - Treatment Outcome
KW  - MedStar Heart & Vascular Institute
KW  - Journal Article
N1  - Available in print through MWHC library: 2002 - present
N2  - BACKGROUND: Recent studies suggest the Orsiro sirolimus-eluting stent (O-SES), which has ultrathin struts with a biodegradable sirolimus-eluting polymer coating, performed better than contemporary drug-eluting stents (DES). We performed a meta-analysis to compare clinical outcomes for all randomized controlled trials (RCTs) of O-SES vs contemporary DES; CONCLUSION: Overall, the Orsiro SES had similar clinical outcomes to contemporary DES with a trend toward reduction in myocardial infarction and stent thrombosis; Copyright (c) 2017 Elsevier Inc. All rights reserved; METHODS/MATERIALS: PubMed, Cochrane CENTRAL, and meeting abstracts were searched for all RCTs comparing O-SES with contemporary DES. Pooled estimates of longest available clinical outcomes at a minimum of one-year follow-up, presented as odds ratios (OR) [95% confidence intervals], were generated with random-effect models; RESULTS: We included 8 RCTs with a total of 11,176 patients (5444 O-SES and 5732 contemporary DES [3537 EES, 1295 ZES, and 1264 BP-BES) with a mean age of 65+/-11, 74% were male, 40% underwent PCI for stable angina, and 56% for ACS. We assessed outcomes comparing O-SES vs. everolimus-eluting stents, vs. permanent-polymer DES, and vs. all DES including biodegradable-polymer DES. Orsiro performed comparably in all categories with a trend toward a reduction in myocardial infarction (0.83 [0.68, 1.02], p=0.07) and stent thrombosis (0.75 [0.54, 1.04], p=0.08)
UR  - https://dx.doi.org/10.1016/j.carrev.2017.11.009
ER  -